Aytu Bioscience Inc. CEO Josh Disbrow told BioWorld Today that confusion over what endpoints might be acceptable to the FDA in trials with therapies for low testosterone "is a bit of an anomaly, and frankly we view it to some degree as a barrier to entry that's relatively unique." In any case, the market for topical treatments "isn't going away," he said.